About Aditya Bardia, MD, MPH

Dr. Bardia is a board-certified medical oncologist interested in developing successful targeted and personalized therapies to improve the outcomes of patients and families afflicted with breast cancer. The accurate identification of target is crucial for success of targeted therapies, and Dr. Bardia is involved in the clinical development of tumor genotyping as well as circulating tumor cells (CTCs) to facilitate accurate diagnosis, therapy selection, and real-time monitoring of breast cancer. In collaboration the CTC center and Haber lab, his research on molecular changes in CTCs in metastatic breast cancer has elucidated the role of epithelial-mesenchymal transition, and provided proof-of-principle that ex-vivo CTC culture and molecular drug testing is feasible in breast cancer. Dr. Bardia is the principal investigator of clinical trials investigating the role of targeted therapy combinations for breast cancer. Dr. Bardia is the recipient of Young Investigator Award from the ASCO Conquer Cancer Foundation.

Departments, Centers, & Programs:

Clinical Interests:




55 Fruit Street
Boston, MA 02114-2696
Phone: 617-726-6500
Phone: 617-724-4800
Fax: 617-643-0589

Medical Education

  • MBBS, All India Institute of Medical Sciences
  • MPH, University of Iowa College of Public Health
  • Residency, All India Institute of Medical Sciences
  • Residency, Mayo Clinic
  • Fellowship, The Johns Hopkins Hospital

American Board Certifications

  • Medical Oncology, American Board of Internal Medicine
  • Internal Medicine, American Board of Internal Medicine

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


  • View my most recent publications at PubMed

    Select Publications:

    • Yu M, Bardia A, Aceto N, et al. Ex Vivo Culture of Circulating Breast Tumor Cells for Individualized Testing of Drug Susceptibility. Science. 2014. 345(6193):216-20.
    • Bardia A, Haber DA. Solidifying Liquid Biopsies: Can circulating tumor cell monitoring guide treatment selection in breast cancer? J Clin Oncol. 2014;32(31):3470-1.
    • Keenan TE, Moy B, Mroz EA, Ross K, Niemierko A, Rocco JW, Isakoff S, Ellisen LW, Bardia A. Comparison of the genomic landscape between primary breast cancer in African American versus White women and association of racial differences with tumor recurrence. J Clin Oncol. 2015.
    • Bardia A, Mayer IA, Diamond JR, et al. Efficacy and safety of anti-Trop-2 antibody drug conjugate Sacituzumab Govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. J Clin Oncol. 2017. Jul 1;35(19):2141-2148.
    • Bardia A, Parton M, Kümmel S, et al. Paclitaxel with inhibitor of apoptosis antagonist, LCL161, for localized triple-negative breast cancer, prospectively stratified by gene signature in a biomarker-driven neoadjuvant trial. J Clin Oncol. 2018 Sep 20: JCO2017748392
    • Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O'Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K. Sacituzumab Govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019 Feb 21;380(8):741-751.